HLB Group
Asia, Kyongsang-bukto, South Korea, Ulsan'%3e%3cg id='b'%3e%3cpath id='a' stroke='%23000' stroke-width='2' d='M-6-25H6m-12 3H6m-12 3H6'/%3e%3cuse xlink:href='%23a' y='44'/%3e%3c/g%3e%3cpath stroke='%23fff' d='M0 17v10'/%3e%3ccircle r='12' fill='%23cd2e3a'/%3e%3cpath fill='%230047a0' d='M0-12A6 6 0 0 0 0 0a6 6 0 0 1 0 12 12 12 0 0 1 0-24z'/%3e%3c/g%3e%3cg transform='rotate(-123.69)'%3e%3cuse xlink:href='%23b'/%3e%3cpath stroke='%23fff' d='M0-23.5v3M0 17v3.5m0 3v3'/%3e%3c/g%3e%3c/svg%3e)
Description
HLB Group is an anti-cancer drug development company.
Investor Profile
HLB Group has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series B rounds (top funding stages).
- Majority of deals are located in South Korea.
- Strong thematic focus on Biopharma, Cannabis, Health Care.
Stage Focus
- Series B (100%)
Country Focus
- South Korea (100%)
Industry Focus
- Biopharma
- Cannabis
- Health Care
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
